


SOPHiA GENETICS HRD Solution makes way in Asia Pacific

10 March 2022 | News

To help identify whether cancer patients may respond better to specific treatments



SOPHiA GENETICS has announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies in Taiwan aiming to provide genetic testing to clinicians, is the first institution in Asia Pacific to adopt SOPHiA GENETICS' technology to support HRD testing.

SOFIVA GENOMICS has been deeply involved in the field of clinical medicine and cancer monitoring for many years and found great success while implementing the solution for advanced HRD (Homologous Recombination Deficiency) detection using deep learning with the SOPHiA DDM Platform.

SOFIVA GENOMICS has compared the SOPHiA DDM HRD Solution with alternative solutions on hundreds of ovarian cancer samples and has concluded that SOPHiA GENETICS offered analysis technology to simultaneously detect more HRR (Homologous Recombination Repair) genes, including BRCA 1 and BRCA 2. They evaluated the integrity of the genome to comprehensively detect the HRD status of patients to determine whether they are suitable for treatment with precision therapy.

HRD is a complex biomarker, important for PARP inhibitors that help identify whether cancer patients may respond better to specific treatments. It is found in more than half of all cases of high-grade serous ovarian cancer (HGSOC), which accounts for about 70-80% of all deaths related to ovarian cancer. Its use could ultimately lead to personalized therapies that benefit the 150,000 patients with ovarian cancer on average per year in Asia Pacific.